Skip to main content
. 2000 Jan 1;20(1):8–21. doi: 10.1523/JNEUROSCI.20-01-00008.2000

Fig. 1.

Fig. 1.

The ampakine CX614 increases BDNF mRNA expression in hippocampal explant cultures. A–C, Bright-field photomicrographs of film autoradiograms showing the in situ hybridization localization of BDNF cRNA labeling in sections from a vehicle-control explant (A), an explant treated for 3 hr with 50 μm CX614 (B), and an explant treated for 3 hr with CX614 (50 μm) and then maintained in drug-free media for an additional 15 hr (C). Shown in B, the 3 hr CX614 treatment increased BDNF cRNA labeling in the stratum granulosum (sg) and stratum pyramidale (sp) (regions CA3–CA1). This effect was reversed by 18 hr after drug washout (C). Scale bar, 300 μm.D, Bar graph showing group mean-labeling density values (± SEM; n > 4/group) within the stratum (str.) granulosum of control explants treated for 3 hr with DMSO (con), explants treated for 3 hr with CX614 (50 μm) alone, and explants treated for 3 hr with CX614 (50 μm), followed by drug washout for an additional 15 or 21 hr (for 18 and 24 hr time points, respectively). As shown, CX614 significantly increased BDNF cRNA labeling in the granule cells by 3 hr (p < 0.01 vs control, SNK; overall effect of treatment, p < 0.0005, ANOVA). This increase was eliminated by subsequent 15–21 hr drug washout.